AR and prostate carcinoma: Data from our MYC-driven prostate cancer mouse model, together with a previously published LNCaP model engineered to overexpress MYC, revealed that MYC-driven repression of the AR transcriptional program is not associated with a disengagement of AR or the loss of the H3K27ac mark.